Please provide your email address to receive an email when new articles are posted on . The most frequent cause of death in patients with rheumatoid arthritis-associated interstitial lung disease and ...

Lung transplantation is the only curative treatment for IPF, but most patients are ineligible, necessitating focus on slowing disease progression. Nintedanib is recommended for PPF, while pirfenidone ...

AIM-30 scoring system predicts 30-day mortality risk in IPF patients post-acute exacerbation using eight clinical variables. The system categorizes patients into low, moderate, and high-risk groups, ...

Background: This study aims to elucidate the capability of periostin (POSTN) as a serum biomarker in diagnosing idiopathic pulmonary fibrosis (IPF), assessing disease severity, and predicting acute ...

INGELHEIM, Germany--(BUSINESS WIRE)--New results from a global survey supported by Boehringer Ingelheim 1 reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis ...

Acute exacerbations (AEs) are both common in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) and are a frequent cause of imminent mortality, a retrospective Japanese study suggests.

Please provide your email address to receive an email when new articles are posted on . A pharmacotherapy is needed for patients with small cell lung cancer plus IPF. Patients frequently experienced ...

BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of ...

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast. Back in ...